BridgeBio Oncology Therapeutics, Inc.
BBOT
$9.71
$0.879.84%
NASDAQ
| 06/30/2025 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Net Income | -28.93% | -41.32% | |||
| Total Depreciation and Amortization | 235.19% | 0.00% | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | -48.52% | -17.56% | |||
| Change in Net Operating Assets | 206.93% | 148.54% | |||
| Cash from Operations | -18.85% | 8.01% | |||
| Capital Expenditure | -42.59% | 0.00% | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | -36.45% | -6,396.26% | |||
| Cash from Investing | -37.28% | -6,433.70% | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | -- | -- | |||
| Issuance of Common Stock | -- | -54.92% | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -- | 3,268.74% | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -708.42% | -- | |||
| Cash from Financing | 4,792.08% | 2,902.72% | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | 214.39% | 22,850.57% | |||